Dermata Therapeutics Statistics
Share Statistics
Dermata Therapeutics has 6.38M
shares outstanding. The number of shares has increased by 1122.96%
in one year.
| Shares Outstanding | 6.38M |
| Shares Change (YoY) | 1122.96% |
| Shares Change (QoQ) | 166.11% |
| Owned by Institutions (%) | 38.16% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,016 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 255.04K, so 4.7% of the outstanding
shares have been sold short.
| Short Interest | 255.04K |
| Short % of Shares Out | 4.7% |
| Short % of Float | 7.22% |
| Short Ratio (days to cover) | 1.32 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -0.78 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0 |
| P/FCF Ratio | -0.19 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Dermata Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.79,
with a Debt / Equity ratio of 0.
| Current Ratio | 1.79 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,535,932,625 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.73% in the
last 52 weeks. The beta is 0.59, so Dermata Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | -78.73% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 41.56 |
| Average Volume (20 Days) | 1,506,688 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.51B |
| Net Income | -12.29B |
| EBITDA | -12.29M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8032.22 |
Full Income StatementBalance Sheet
The company has 3.16M in cash and 0 in
debt, giving a net cash position of 3.16M.
| Cash & Cash Equivalents | 3.16M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -65.68M |
| Total Assets | 10.01M |
| Working Capital | 8.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -11.16M
and capital expenditures 0, giving a free cash flow of -11.16M.
| Operating Cash Flow | -11.16M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.16M |
| FCF Per Share | -7.3 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
